PTC Therapeutics

PTC Therapeutics

PTC Therapeutics is measured by moments

At PTC, we are committed to a single goal: to prolong the moments of life for rare disease patients and their families.

Our mission is to provide access to the best treatments for rare disease patients who have few or no treatment options. Whether our therapies grant hours, days, months or years, every little moment is a huge victory – so our greatest achievements are “measured by moments”.

This mission underpins our focus on the discovery, development and global commercialization of clinically differentiated medicines that provide benefits to patients with rare diseases.

As a global, science-driven biopharmaceutical company, we combine our strong clinical and scientific expertise with a dedication to using innovative science and new technologies to find innovative ways to treat these diseases, which can give patients and their families more moments.

Since 1998, PTC has been a biopharmaceutical company focused on small molecules and innovative gene therapies for rare genetic diseases. We have offices and/or research laboratories in more than 20 countries and a commercial presence in over 50 countries worldwide. We also enjoy a strong business performance and a solid capital position.

PTC achieved historic advances in the treatment of Duchenne muscular dystrophy in 2003 and has continued to grow and evolve since then. Through strategic acquisitions and unparalleled scientific research, our team of “brilliant minds” is “measured by moments” brought to patients and caregivers facing challenges of rare diseases such as Duchenne, aromatic amino acid decarboxylase deficiency (AADC), Huntington’s disease, spinal muscular atrophy, and many more.